{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:31:09Z","timestamp":1790101869552,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>The aim of this study was to evaluate the effects of switching to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) refractory to aflibercept treatment and to identify predictive factors for switch response.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective chart review was conducted including 32 eyes from 26 patients with refractory nAMD, who switched from monthly intravitreal aflibercept treatment (\u2265\u20096\u00a0months) to ranibizumab. Outcome measures included changes in visual acuity (VA), intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), and central retinal thickness (CRT), evaluated at 6\u00a0months before switch (T1), at the time of switch (T2), and 3\u00a0months post-switch (T3).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was an increase in CRT from T1 to T2, which decreased after switch from T2 to T3. Regression analysis of the changes per month observed between time points showed significant differences in PED height (<jats:italic>p\u2009=<\/jats:italic>\u00a00.02), SRF (<jats:italic>p\u2009=<\/jats:italic>\u00a00.01), and neuroretinal thickness as a measure for IRF (<jats:italic>p\u2009=<\/jats:italic>\u00a00.03). No significant change was found for VA. Predictive factors for better switch response included an exacerbation between T1 and T2, thicker measurements at T2, male sex, shorter treatment duration before switch, and fewer preceding injections. No association with preceding switch was found.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Patients with nAMD refractory to aflibercept benefit from switching to ranibizumab, particularly those whose condition worsened prior to the switch. This may be explained by drug tolerance to aflibercept. Our findings may facilitate making appropriate treatment decisions, potentially improving patient outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00417-020-04730-8","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T19:03:21Z","timestamp":1589310201000},"page":"1591-1596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"258","author":[{"given":"Liza-Marie","family":"Marquis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmela","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"4730_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/archopht.116.5.653","volume":"116","author":"CCW Klaver","year":"1998","unstructured":"Klaver CCW, Wolfs RCW, Vingerling JR, Hofman A, de Jong PTVM (1998) Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study. Arch Ophthalmol 116:653\u2013658. https:\/\/doi.org\/10.1001\/archopht.116.5.653","journal-title":"Arch Ophthalmol"},{"key":"4730_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"The Eye Diseases Prevalence Research Group*","year":"2004","unstructured":"The Eye Diseases Prevalence Research Group* (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477\u2013485. https:\/\/doi.org\/10.1001\/archopht.122.4.477","journal-title":"Arch Ophthalmol"},{"key":"4730_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"4730_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"4730_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185. https:\/\/doi.org\/10.1007\/s10456-011-9249-6","journal-title":"Angiogenesis"},{"key":"4730_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/OPTH.S33372","volume":"6","author":"M Stewart","year":"2012","unstructured":"Stewart M (2012) Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol 6:1175\u20131186. https:\/\/doi.org\/10.2147\/OPTH.S33372","journal-title":"Clin Ophthalmol"},{"key":"4730_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","volume":"92","author":"MW Stewart","year":"2008","unstructured":"Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 92:667. https:\/\/doi.org\/10.1136\/bjo.2007.134874","journal-title":"Br J Ophthalmol"},{"key":"4730_CR8","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/DDDT.S97653","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 10:1857\u20131867. https:\/\/doi.org\/10.2147\/DDDT.S97653","journal-title":"Drug Des Devel Ther"},{"key":"4730_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/OPTH.S160367","volume":"12","author":"A Dirani","year":"2018","unstructured":"Dirani A, Mantel I (2018) Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. Clin Ophthalmol 12:593\u2013600. https:\/\/doi.org\/10.2147\/OPTH.S160367","journal-title":"Clin Ophthalmol"},{"key":"4730_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ajo.2014.11.022","volume":"159","author":"CA Arcinue","year":"2015","unstructured":"Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR (2015) One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol 159:426\u2013436.e2. https:\/\/doi.org\/10.1016\/j.ajo.2014.11.022","journal-title":"Am J Ophthalmol"},{"key":"4730_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1097\/IAE.0000000000000813","volume":"36","author":"S de Massougnes","year":"2016","unstructured":"de Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I (2016) Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects. Retina 36:881\u2013888. https:\/\/doi.org\/10.1097\/IAE.0000000000000813","journal-title":"Retina"},{"key":"4730_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ajo.2013.02.009","volume":"156","author":"VY Ho","year":"2013","unstructured":"Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB (2013) Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 156:23\u201328.e2. https:\/\/doi.org\/10.1016\/j.ajo.2013.02.009","journal-title":"Am J Ophthalmol"},{"key":"4730_CR13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","volume":"33","author":"N Kumar","year":"2013","unstructured":"Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605\u20131612. https:\/\/doi.org\/10.1097\/IAE.0b013e31828e8551","journal-title":"Retina"},{"key":"4730_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2013.02.017","volume":"156","author":"B Bakall","year":"2013","unstructured":"Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB (2013) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156:15\u201322.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.02.017","journal-title":"Am J Ophthalmol"},{"key":"4730_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ophtha.2013.08.035","volume":"121","author":"AA Chang","year":"2014","unstructured":"Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M (2014) Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 121:188\u2013192. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.035","journal-title":"Ophthalmology"},{"key":"4730_CR16","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00417-014-2589-3","volume":"252","author":"H Fassnacht-Riederle","year":"2014","unstructured":"Fassnacht-Riederle H, Becker M, Graf N, Michels S (2014) Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 252:1705\u20131709. https:\/\/doi.org\/10.1007\/s00417-014-2589-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4730_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/497178","volume":"2014","author":"DR Griffin","year":"2014","unstructured":"Griffin DR, Richmond PP, Olson JC (2014) Intravitreal aflibercept outcomes in patients with persistent macular exudate previously treated with bevacizumab and\/or ranibizumab for neovascular age-related macular degeneration. J Ophthalmol 2014:1\u20136. https:\/\/doi.org\/10.1155\/2014\/497178","journal-title":"J Ophthalmol"},{"key":"4730_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00417-015-3084-1","volume":"254","author":"R Despreaux","year":"2016","unstructured":"Despreaux R, Cohen SY, Semoun O, Zambrowski O, Jung C, Oubraham H, Souied EH (2016) Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Graefes Arch Clin Exp Ophthalmol 254:639\u2013644. https:\/\/doi.org\/10.1007\/s00417-015-3084-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4730_CR19","doi-asserted-by":"publisher","first-page":"314251","DOI":"10.1136\/bjophthalmol-2019-314251","volume":"2019","author":"RP Gale","year":"2019","unstructured":"Gale RP, Pearce I, Eter N et al (2019) Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol 2019:314251. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314251","journal-title":"Br J Ophthalmol"},{"key":"4730_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40942-016-0028-9","volume":"2","author":"GR Slean","year":"2016","unstructured":"Slean GR, Hemarat K, Khurana RN, Stewart JM (2016) Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series. Int J Retina Vitreous 2:2. https:\/\/doi.org\/10.1186\/s40942-016-0028-9","journal-title":"Int J Retina Vitreous"},{"key":"4730_CR21","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00417-017-3762-2","volume":"255","author":"P Parvin","year":"2017","unstructured":"Parvin P, Zola M, Dirani A, Ambresin A, Mantel I (2017) Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with aflibercept. Graefes Arch Clin Exp Ophthalmol 255:2127\u20132134. https:\/\/doi.org\/10.1007\/s00417-017-3762-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4730_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/eye.2014.258","volume":"29","author":"C Gianniou","year":"2015","unstructured":"Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I (2015) Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye 29:342\u2013349. https:\/\/doi.org\/10.1038\/eye.2014.258","journal-title":"Eye"},{"key":"4730_CR23","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/bjophthalmol-2013-304556","volume":"98","author":"I Mantel","year":"2014","unstructured":"Mantel I, Niderprim S-A, Gianniou C, Deli A, Ambresin A (2014) Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol 98:1192\u20131196. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304556","journal-title":"Br J Ophthalmol"},{"key":"4730_CR24","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, Sakaguchi H, Nishida K (2019) Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol 257:2559\u20132569. https:\/\/doi.org\/10.1007\/s00417-019-04456-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4730_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2011-301236","volume":"96","author":"S Binder","year":"2012","unstructured":"Binder S (2012) Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 96:1\u20132. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301236","journal-title":"Br J Ophthalmol"},{"key":"4730_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, De\u00e1k GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM (2014) Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 121:1237\u20131245. https:\/\/doi.org\/10.1016\/j.ophtha.2013.12.029","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-04730-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T23:52:37Z","timestamp":1620777157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-04730-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4730"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04730-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Swiss Federal Department of Health for retrospective data analysis and was performed in accordance with the ethical standards of the Declaration of Helsinki. Informed consent was waived by the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}